SFCM
NKTR icon

Seven Fleet Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Seven Fleet Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$309K Sell
4,300
-10,700
-71% -$609K 0.1% 96
2025
Q4 		$634K Buy
+15,000
New +$839K 0.43% 42

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Seven Fleet Capital Management's NKTR Position: Q1 2026 in Review

Seven Fleet Capital Management reduced its Nektar Therapeutics (NKTR) stake by 71% in Q1 2026, selling an estimated $609K and leaving 4,300 shares worth $309K. The position accounts for 0.1% of the portfolio, ranked #96.

Seven Fleet Capital Management first reported a position in NKTR in Q4 2025 and has held it in 2 quarters since. The position peaked at $634K in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Seven Fleet Capital Management held 4,300 shares of Nektar Therapeutics worth $309K as of Q1 2026.
  • Seven Fleet Capital Management sold 10,700 Nektar Therapeutics shares in Q1 2026, an estimated $609K.
  • Nektar Therapeutics made up 0.1% of Seven Fleet Capital Management's portfolio in Q1 2026, its #96 holding.
  • Seven Fleet Capital Management first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Seven Fleet Capital Management's Nektar Therapeutics position peaked at $634K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.